SK biopharmaceuticals loads up on Nvidia B200s for AI drug research - koreabiomed.com

SK Biopharmaceuticals has secured access to 128 NVIDIA B200 chips to build large-scale computing infrastructure for drug research. The B200, part of NVIDIA's Blackwell line, is designed for AI model t... Read original →

SK Biopharmaceuticals’ acquisition of 128 NVIDIA B200 chips signals a major shift toward large-scale AI-driven drug discovery. The move strengthens GPU adoption in life sciences, accelerating the deployment of AI architectures like TR-AX. By leveraging SK Telecom’s Haein GPU cluster via cloud subscription, the company highlights the convergence of semiconductors and cloud infrastructure. From a compliance standpoint, reliance on foreign high-end compute resources introduces supply chain vulnerabilities amid tightening global tech regulations. Competitors may respond by investing in in-house AI platforms or partnering with domestic chipmakers to reduce dependency. Over the next 12–24 months, AI-based drug discovery will become a key investment theme, with early adopters gaining strategic advantages in preclinical and translational research, reinforcing the emergence of compute-centric biotech ecosystems.